Scientists at Albert Einstein College of Medicine at Yeshiva University have discovered what could prove to be a new cancer treatment for head and neck cancers.
While conducting research into an HDAC inhibitor called LBH589 to treat cancers of the blood, the research team found that the compound had some effect on destroying head and neck cancer tumours.
Dr Richard Smith, the lead clinician involved in the study, commented: "This report shows that an HDAC inhibitor is effective on head and neck cancer cell lines and that is the first step toward use in humans."
Chair and professor of pathology at Einstein Dr Michael Prystowsky, who co-authored the study, added that the lab results will next be tested on mice and if confirmed, will then be used in clinical trials of humans to treat head and neck cancer.
There are at least 30 different areas within the head and neck where cancer may develop.